Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients-Reference-Cited by-同舟云学术

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients

Published:2019-09-30 Issue:3 Volume:54 Page:198-203
ISSN:2287-979X
Container-title:BLOOD RESEARCH
language:en
Short-container-title:Blood Res

Author:

You Chur Woo¹,Baek Hee Jo²,Park Sang Kyu³,Park Young Shil⁴,Shin Ho-Jin⁵,Engl Werner⁶,Tangada Srilatha⁷

Affiliation:

1. Eulji University Hospital, Daejeon, Korea

2. Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea

3. Ulsan University Hospital, Ulsan, Korea

4. Kyung Hee University Hospital at Gangdong, Seoul, Korea

5. Pusan National University Hospital, Busan, Korea

6. Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria

7. Baxalta US Inc., a Takeda Company, Cambridge, MA, USA

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://synapse.koreamed.org/pdf/10.5045/br.2019.54.3.198

Reference20 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. Guidelines for the management of hemophilia

3. National Center on Birth Defects and Developmental Disabilities. What is hemophilia?. Atlanta, GA. Centers for Disease Control and Prevention. 2018. March 13, 2019. https://www.cdc.gov/ncbddd/hemophilia/facts.html

4. World Federation of Hemophilia. Severity of hemophilia. Quebec, Canada. World Federation of Hemophilia. 2012. March 13, 2019. https://www.wfh.org/en/page.aspx?pid=643

5. Korea hemophilia foundation registry trends 1991-2012: patient registry, demographics, health services utilization

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials;F1000Research;2022-01-13

2. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials;F1000Research;2021-11-11

3. Efficacy safety and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials;F1000Research;2021-10-15